|
1.
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
3.
|
Blum HE: Hepatocellular carcinoma: therapy
and prevention. World J Gastroenterol. 11:7391–7400.
2005.PubMed/NCBI
|
|
4.
|
Marzo I, Brenner C, Zamzami N, Susin SA,
Beutner G, Brdiczka D, Remy R, Xie ZH, Reed JC and Kroemer G: The
permeability transition pore complex: a target for apoptosis
regulation by caspases and bcl-2-related proteins. J Exp Med.
187:1261–1271. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Marzo I, Brenner C, Zamzami N,
Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama
S, Reed JC and Kroemer G: Bax and adenine nucleotide translocator
cooperate in the mitochondrial control of apoptosis. Science.
281:2027–2031. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Dolce V, Scarcia P, Iacopetta D and
Palmieri F: A fourth ADP/ATP carrier isoform in man:
identification, bacterial expression, functional characterization
and tissue. FEBS Lett. 579:633–637. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lunardi J and Attardi G: Differential
regulation of expression of the multiple ADP/ATP translocase genes
in human cells. J Biol Chem. 266:16534–16540. 1991.PubMed/NCBI
|
|
8.
|
Le Bras M, Borgne-Sanchez A, Touat Z, El
Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire
C, Kroemer G, Jacotot E and Brenner C: Chemosensitization by
knockdown of adenine nucleotide translocase-2. Cancer Res.
66:9143–9152. 2006.PubMed/NCBI
|
|
9.
|
Faure Vigny H, Heddi A, Giraud S, Chautard
D and Stepien G: Expression of oxidative phosphorylation genens in
renal tumors and tumoral cell lines. Mol Carcinog. 16:165–172.
1996.PubMed/NCBI
|
|
10.
|
Chevrollier A, Loiseau D, Chabi B, Renier
G, Donay O, Malthiery Y and Stepien G: ANT2 isoform required for
cancer cell glycolysis. J Bioenerg Biomembr. 37:307–316. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Chevrollier A, Loiseau D, Gautier F,
Malthlery Y and Stepien G: ANT2 expression under hypoxic conditions
produces opposite cell-cycle behavior in 143B and HepG2 cancer
cells. Mol Carcinog. 42:1–8. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chevrollier A, Loiseau D and Stepien G:
What is the specific role of ANT2 in cancer cells? Med Sci (Paris).
21:156–161. 2005.(In French).
|
|
13.
|
Jang JY, Choi Y, Jeon YK and Kim CW:
Suppression of adenine nucleotide translocase-2 by vector-based
siRNA in human breast cancer cells induces apoptosis and inhibits
tumor growth in vitro and in vivo. Breast Cancer Res. 10:R112008.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Yoshikawa H, Matsubara K, Qian GS, Jackson
P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a
negative regulator of the JAK/STAT pathway, is silenced by
methylation in human hepatocellular carcinoma and shows
growth-suppression activity. Nat Genet. 28:29–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Singal R and Ginder GD: DNA methylation.
Blood. 93:4059–4070. 1999.PubMed/NCBI
|
|
16.
|
Robertson KD and Jones PA: DNA
methylation: past, present and future directions. Carcinogenesis.
21:461–467. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Baylin SB, Esteller M, Rountree MR,
Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA
methylation, chromatin formation and gene expression in cancer. Hum
Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Heinrich PC, Behrmann I, Muller-Newen G,
Schaper F and Graeve L: Interleukin-6-type cytokine signaling
through the gp130/Jak/STAT pathway. Biochem J. 334:297–314.
1998.PubMed/NCBI
|
|
19.
|
Imada K and Leonard WJ: The Jak-STAT
pathway. Mol Immunol. 37:1–11. 2000. View Article : Google Scholar
|
|
20.
|
Alexander WS, Starr R, Metcalf D,
Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson
R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S,
Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA and Hilton DJ:
Suppressors of cytokine signaling (SOCS): negative regulators of
signal transduction. J Leukoc Biol. 66:588–592. 1999.PubMed/NCBI
|
|
21.
|
Nicola NA and Greenhalgh CJ: The
suppressors of cytokine signaling (SOCS) proteins: important
feedback inhibitors of cytokine action. Exp Hematol. 28:1105–1112.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
He B, You L, Uematsu K, Zang K, Xu Z, Lee
AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently
silenced by hypermethylation and suppresses cell growth in human
lung cancer. Proc Natl Acad Sci USA. 100:14133–14138. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
He B, You L, Xu Z, Mezieres J, Lee AY and
Jablons DM: Activity of the suppressor of cytokine signaling-3
promoter in human non-small-cell lung cancer. Clin Lung Cancer.
5:366–370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Weber A, Hengge UR, Bardenheuer W,
Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C and
Tannapfel A: SOCS-3 is frequently methylated in head and neck
squamous cell carcinoma and its precursor lesions and causes growth
inhibition. Oncogene. 24:6699–6708. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Chu PY, Yeh CM, Hsu NC, Chang YS, Chang JG
and Yeh KT: Epigenetic alteration of the SOCS1 gene in
hepatocellular carcinoma. Swiss Med Wkly. 140:w130652010.PubMed/NCBI
|
|
26.
|
Isomoto H, Kobayashi S, Werneburg NW,
Bronk SF, Guicciardi ME, Frank DA and Gores GJ: Interleukin 6
upregulates myeloid cell leukemia-1 expression through a STAT3
pathway in cholangiocarcinoma cells. Hepatology. 42:1329–1338.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Konnikova L, Kotecki M, Kruger MM and
Cochran BH: Knockdown of STAT3 expression by RNAi induces apoptosis
in astrocytoma cells. BMC Cancer. 3:1–9. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Aoki Y, Feldman GM and Tosato G:
Inhibition of STAT3 signaling induces apoptosis and decreases
survivin expression in primary effusion lymphoma. Blood.
101:1535–1542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Jourdan M, Veyrune JL, Vos JD, Redal N,
Couderc G and Klein B: A major role for Mcl-1 antiapoptotic protein
in the IL-6-induced survival of human myeloma cells. Oncogene.
22:2950–2959. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk
ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN
and CYLD are part of the epigenetic switch linking inflammation to
cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lacronique V, Boureux A, Valle VD, Poirel
H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael
J and Bernard OA: A TEL-JAK2 fusion protein with constitutive
kinase activity in human leukemia. Science. 278:1309–1312. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
|
|
33.
|
Cooney RN: Suppressors of cytokine
signaling (SOCS): inhibitors of the Jak/STAT pathway. Shock.
17:83–90. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Okochi O, Hibi K, Sakai M, Inoue S, Takeda
S, Kaneko T and Nakao A: Methylation-mediated silencing of SOCS-1
gene in hepatocellular carcinoma derived from cirrhosis. Clinical
Cancer Res. 9:5295–5298. 2003.PubMed/NCBI
|
|
35.
|
Sun L, Hui AM, Kanai Y, Sakamoto M and
Hirohashi S: Increased DNA methyltransferase expression is
associated with an early stage of human hepatocarcinogenesis. Jpn J
Cancer Res. 88:1165–1170. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Saito Y, Kanai Y, Sakamoto M, Saito H,
Ishii H and Hirohashi S: Expression of mRNA for DNA
methyltransferases and methyl-CpG-binding proteins and DNA
methylation status on CpG islands and pericentromeric
pericentromeric satellite regions during human
hepatocarcinogenesis. Hepatology. 33:561–568. 2001. View Article : Google Scholar
|
|
37.
|
Kanai K, Ushijima S, Kondo Y, Nakanishi Y
and Hirohashi S: DNA methyltransferase expression and DNA
methylation of CpG islands and peri-centromeric satellite regions
in human colorectal and stomach cancers. Int J Cancer. 91:205–212.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu
F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C,
Ramaswamy B, Shapiro CL, Lin HJL, Cheng ASL, Jin VX and Huang TH:
Epigenetic silencing mediated through activated PI3K/AKT signaling
in breast cancer. Cancer Res. 71:1752–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Zhang B, Wang Q and Pan X: MicroRNAs and
their regulatory roles in animals and plants. J Cell Physiol.
210:279–289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Jiang Q, Wang Y, Hao Y, Juan L, Teng M,
Zhang X, Li M, Wang G and Liu Y: miR2 Disease: a manually curated
database for microRNA deregulation in human disease. Nucleic Acids
Res. 37:D98–D104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Meng F, Enson R, Wehbe-Janek H, Ghoshal K,
Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN
tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Hatley ME, Patrick DM, Garcia MR,
Richardson JA, Duby RB, van Rooij E and Olson EN: Modulation of
K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell.
18:282–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
